Chronic Kidney Disease

The author discusses how value-based payment models in chronic kidney disease can improve total cost and quality of care for patienst with chronic kidney disease (CKD).

A study evaluating whether a virtual platform can improve access to evaluations for kidney transplants found that surgical teams could continue to keep up with evaluations adding patients to wait lists during the pandemic.

Bringing together genetic work with social determinants of health can improve understanding of factors associated with ESKD disparities, said Adriana Hung, MD, MPH, associate professor of medicine at Vanderbilt University, and Bryce Rowan, a statistical genetic analyst.

An observational study showed that it may be more effective to start patients on a renin-angiotensin system inhibitor (RASi) than a calcium channel blocker in delaying progression of advanced kidney disease.

Patients with COVID-19 and end-stage renal disease were 11 times more likely to be admitted to the hospital than patients without kidney disease.

A variety of factors contributed to discontinuation rates in FIDELIO-DKD, said George Bakris, MD, professor of medicine and director of the American Heart Association Comprehensive Hypertension Center at the University of Chicago Medicine.

As higher estimated glomerular filtration rate (eGFR) equations indicate better kidney function, there has been increasing recognition that this may lead to inequitable and delayed care in treating chronic kidney disease (CKD) in Black adults.

Making sure patients have a strong medical home and close follow-up is one way to reduce glomerular disease disparities among children, said Jill Krissberg, MD, a pediatric nephrology fellow at Stanford University School of Medicine.

Jackson Williams is vice president, public policy at Dialysis Patient Citizens. Previously he worked at the Centers for Medicare and Medicaid Services (CMS); was a health services researcher in the AARP Public Policy Institute; and a lobbyist on health policy issues for 3 nonprofit associations. His more than 2 decades of experience monitoring, studying, and overseeing federal demonstration projects include time as a project officer at CMMI and serving as the consumer representative on a Medicare pilot site’s governing body.

If results from FIGARO-DKD are as positive as those of FIDELIO-DKD, the field will work aggressively to get the message out, said George Bakris, MD, professor of medicine and director of the American Heart Association Comprehensive Hypertension Center at the University of Chicago Medicine.

In the FIDELIO-DKD trial researchers purposely recruited centers that had very large African American databases, said George Bakris, MD, professor of medicine and director of the American Heart Association Comprehensive Hypertension Center at the University of Chicago Medicine.

A new analysis of CREDENCE data showed that the sodium-glucose cotransporter 2 (SGLT2) inhibitor worked in advanced disease and without causing acute kidney injury.

The FIDELIO-DKD program is perhaps just the beginning of seeing how finerenone can be used, said Rajiv Agarwal, MD, MS, FASN, a professor of medicine at Indiana University School of Medicine and a staff physician at the Veterans Affairs Medical Center in Indianapolis, Indiana.

Primary care physicians did not refer the majority of patients with severe nephropathy to specialists; nonreferred patients had fewer comorbidities and might be better kidney transplant candidates.

Authors from the American Society of Nephrology and Kidney Care Partners discuss the response of the kidney care community to the COVID-19 pandemic.

The federal illegality and Schedule I listing of cannabis significantly impair our ability to conduct any kind of prospective clinical research, said Joshua L Rein, DO, FASN, a nephrologist at Mt. Sinai Hospital in New York City.

A pair of abstracts presented at Kidney Week 2020 underscore the relationship between social determinants of health (SDOH) and chronic kidney disease (CKD) in military populations and the challenges of tracking these factors.

New results from EMPEROR-Reduced presented at Kidney Week 2020.

Prompted by students, the medical school overturned a longstanding diagnostic protocol that was not well-founded in evidence.

For-profit dialysis centers are spending heavily to defeat the measure.

The recent focus on disparities in health care comes through in the call to action.

The FDA action follows presentation of results in August during the European Society of Cardiology 2020 Virtual Congress.

A new analysis shows that ertugliflozin matched renal results seen in trials for a pair of rival sodium glucose cotransporter 2 (SGLT2) inhibitors.

Nivolumab, a checkpoint inhibitor, and cabozantinib, a targeted therapy, produced dramatic results when used in combination for patients with newly diagnosed advanced kidney cancer.

Researchers suggest that clinical trial design could be shaped by measuring reductions in urinary protein.